Beyond antibodies: New affinity reagents to unlock the proteome
Open Access
- 6 January 2014
- journal article
- editorial
- Published by Wiley in Proteomics
- Vol. 14 (6), 638-644
- https://doi.org/10.1002/pmic.201300187
Abstract
Antibodies have been the workhorse reagents of protein capture and quantification since their 1959 debut in the RIAs developed by Yalow and Berson. However, there are technical challenges to the use of antibodies in highly multiplexed arrays aimed at measuring hundreds or even thousands of proteins at one time. We describe here a recently developed class of synthetic protein-binding reagents (slow off-rate modified aptamer). We discuss the chemical makeup and protein binding specifications of slow off-rate modified aptamer reagents, compare them to traditional aptamers and antibodies, briefly describe the novel proteomic assay that takes advantage of their unique properties, and provide several examples of their multiple applications to biomarker discovery and validation across a range of biomedical science questions.Keywords
This publication has 54 references indexed in Scilit:
- Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targetsProceedings of the National Academy of Sciences of the United States of America, 2012
- Challenges and Opportunities for Small Molecule Aptamer DevelopmentJournal of Nucleic Acids, 2012
- Antigen–antibody interface properties: Composition, residue interactions, and features of 53 non-redundant structuresBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- Age-Dependent Changes in the Cerebrospinal Fluid Proteome by Slow Off-Rate Modified Aptamer ArrayThe American Journal of Pathology, 2012
- From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic AssayPLOS ONE, 2011
- Beyond natural antibodies: the power of in vitro display technologiesNature Biotechnology, 2011
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung CancerPLOS ONE, 2010
- The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipelineProteomics – Clinical Applications, 2008
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990